Posted on November 17, 2020 by Sitemaster
If you are someone who can spare a few bucks to support research into prostate cancer (and particularly the more aggressive forms of prostate cancer), please read on … READ MORE …
Filed under: Living with Prostate Cancer | Tagged: donate, PCF, research | Leave a comment »
Posted on November 16, 2020 by Sitemaster
A recent report in the CDC’s Morbidity and Mortality Weekly Report (MMWR) may offer one of the best analyses of an increasing risk for diagnosis with and death from advanced forms of prostate cancer over the period from 2003 to 2017 (the last year for which we have accurate data from the SEER database). … READ MORE …
Filed under: Diagnosis, Living with Prostate Cancer, Management, Treatment | Tagged: CDC, Diagnosis, epidemiology, incidence, mortality, risk | 3 Comments »
Posted on November 13, 2020 by Sitemaster
The following article was written by two of the founders of Active Surveillance Patients International (ASPI) under the title “Al Roker’s forecast: rising PSA and a radical prostatectomy” and distributed largely by e-mail. It is re-posted here with the permission of the authors. … READ MORE …
Filed under: Diagnosis, Living with Prostate Cancer, Risk | Tagged: active, celebrity, Roker, surveillance | 4 Comments »
Posted on October 28, 2020 by Sitemaster
Perhaps unsurprisingly, your sitemaster was a little distracted on March 9 this year (by both the start of the COVID-19 chaos and by his birthday) and so he utterly missed what appears to be a rather important paper on the use of 5α-reductase inhibitors (5-ARIs) in men on active surveillance (AS) for management of low-risk forms of prostate cancer.
… READ MORE …
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: 5-ARI, active, AS, Prevention, progression, surveillance | 2 Comments »
Posted on October 27, 2020 by Sitemaster
We hear that an investigational drug called onvansertib — a so-called polo-like kinase 1 (PLK1) inhibitor — may have benefit in the treatment of men with metastatic, castration-resistant prostate cancer (mCRPC) who are showing early signs of progression on treatment with abiraterone acetate (Zytiga) + prednisone.
… READ MORE …
Filed under: Drugs in development, Living with Prostate Cancer, Management, Treatment | Tagged: abiraterone, castration-resistant, mCRPC, metastatic, onvansertib, Treatment, trial | 1 Comment »
Posted on October 27, 2020 by Sitemaster
New data on this topic — from a Phase II/III clinical trial — have just been presented at the virtual annual meeting of the American Society for Radiation Oncology (ASTRO). Basically, the data from this study by Sahgal et al. indicated that 24 Gy (in two 12 Gy doses) of stereotactic body radiation therapy (SBRT) was more effective in the elimination of spinal pain in patients with metastatic cancer as compared to 20 Gy (in five 4 Gy doses) of conventional, external beam radiation therapy (EBRT).
… READ MORE …
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: bone, EBRT, metastatic, pain, radiation, SBRT, spine | 3 Comments »
Posted on October 15, 2020 by Sitemaster
A new type of “educational” service has been brought to our attention that uses virtual reality (VR) systems allowing a number of opportunities for men to “talk” to a virtual prostate cancer patient about their own risks for prostate cancer and things like the risks and benefits of PSA testing. … READ MORE …
Filed under: Diagnosis, Living with Prostate Cancer, Management, Risk, Treatment | Tagged: knowledge, patient, risk, testing, Treatment, virtual | 3 Comments »
Posted on October 15, 2020 by Sitemaster
So there are new, interesting data regarding the treatment of men with metastatic, castration-resistant prostate cancer (mCRPC) with sipuleucel-T (Provenge) as well as either or both of abiraterone acetate (Zytiga) and enzalutamide (Xtandi) — known generically as androgen-receptor signaling pathway inhibitors or ASPIs. … READ MORE …
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: castration-resistant, mCRPC, metastatic, Provenge, sipuleucel-T, survival | 2 Comments »
Posted on September 28, 2020 by Sitemaster
The following article was originally published in the ASCO Connection magazine on September 22, 2020 (click here for the original). It was written by Anne Katz, PhD, RN, FAAN, a certified sexuality counselor at CancerCare Manitoba and nurse counselor at the Manitoba Prostate Centre. … READ MORE …
Filed under: Living with Prostate Cancer | Tagged: distress, genital, penile, shrinkage | 5 Comments »
Posted on September 21, 2020 by Sitemaster
Roche/Genentech’s investigational drug ipatasertib has demonstrated a small but statistically significant benefit in the treatment of men with metastatic, castration-resistant prostate cancer (mCRPC) who had tumors exhibiting loss of the phosphatase and tensin (PTEN) homolog: a 2-month improvement in median radiographic progression-free survival (rPFS). … READ MORE …
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: castration-resistant, ipatasertib, IPATential150, loss, metastatic, PTEN | 7 Comments »
Posted on September 10, 2020 by Sitemaster
At the end of this month, on Tuesday, September 29, at 8:00-9:30 p.m. Eastern time (to be precise), there will be a second webinar in the series on the role of active surveillance in the management of favorable-risk forms of localized prostate cancer, coordinated by our good friend Howard Wolinsky and others. … READ MORE …
Filed under: Diagnosis, Living with Prostate Cancer, Management, Risk | Tagged: active, genetics, genomics, Helfand, surveillance, webinar | 3 Comments »
Posted on September 10, 2020 by Sitemaster
In 2013, Zumsteg et al. proposed a refinement in the NCCN “intermediate risk” classification into two subcategories, “favorable intermediate-risk (FIR)” and “unfavorable intermediate-risk (UIR).” … READ MORE …
Filed under: Diagnosis, Living with Prostate Cancer, Management, Risk, Treatment | Tagged: adjuvant, ADT, favorable, intermediate, radiation, risk, unfavorable | 3 Comments »
Posted on August 29, 2020 by Sitemaster
The Prostate Active Surveillance Study (PASS), initially funded by the Canary Foundation, is a multi-center research study for men with low-risk disease who have chosen active surveillance (AS) to manage their prostate cancer. Active surveillance in PASS means closely monitoring men with prostate cancer and offering treatment if test results show the cancer is getting worse. … READ MORE …
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: active, AS, calculator, PASS, progression, risk, surveillance | Leave a comment »
Posted on August 26, 2020 by Sitemaster
Earlier today we reported on a recent publication based on data from the CaPSURE registry database, which stated that, among men enrolled in that database, men died sooner from their prostate cancer after they progressed to having metastatic disease over time (median survival, 2.4 years from onset of metastasis) than died from their prostate cancer if they were initially diagnosed with metastatic disease (median survival, 5.3 years). … READ MORE …
Filed under: Diagnosis, Living with Prostate Cancer, Management, Treatment | Tagged: castration-resistant, Diagnosis, metastatic, mortality, survival | 3 Comments »
Posted on August 26, 2020 by Sitemaster
Some readers are probably going to find this very hard to believe, but … according to a newly published study, men initially diagnosed with metastatic prostate cancer are actually less likely to die from their cancer than men who are initially diagnosed with non-metastatic disease but who progress to having metastatic disease over time. … READ MORE …
Filed under: Diagnosis, Living with Prostate Cancer, Management | Tagged: cancer-specific, Diagnosis, metastatic, mortality, survival | 5 Comments »
